DXR vs TFX vs HOLX vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -93. 8% for Daxor Corporation (DXR). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Teleflex Incorporated (TFX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Daxor Corporation at 87. 8x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus TFX's -10. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Daxor Corporation (DXR) is the lower-risk stock at 0.

33β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 570% more volatile than DXR relative to the S&P 500. On balance sheet safety, Daxor Corporation (DXR) carries a lower debt/equity ratio of 2% versus 87% for Teleflex Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -93. 8% for Daxor Corporation (DXR). On earnings-per-share growth, the picture is similar: Daxor Corporation grew EPS 81. 5% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Daxor Corporation (DXR) is the more profitable company, earning 25.

2% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps 25. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXR leads at 29. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — DXR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 19. 6x for Teleflex Incorporated — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, TFX (1.

0% yield) pays a dividend. DXR, HOLX, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Daxor Corporation (DXR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DXR: +21. 9%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TFX pays a dividend while DXR, HOLX, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.